Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 22078567)

1.

Structural basis for μ-opioid receptor binding and activation.

Serohijos AW, Yin S, Ding F, Gauthier J, Gibson DG, Maixner W, Dokholyan NV, Diatchenko L.

Structure. 2011 Nov 9;19(11):1683-90. doi: 10.1016/j.str.2011.08.003.

2.

Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop.

Bonner G, Meng F, Akil H.

Eur J Pharmacol. 2000 Sep 1;403(1-2):37-44.

PMID:
10969141
3.
4.

ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone.

Li JG, Chen C, Yin J, Rice K, Zhang Y, Matecka D, de Riel JK, DesJarlais RL, Liu-Chen LY.

Life Sci. 1999;65(2):175-85.

PMID:
10416823
5.
7.

Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.

Zhang P, Johnson PS, Zöllner C, Wang W, Wang Z, Montes AE, Seidleck BK, Blaschak CJ, Surratt CK.

Brain Res Mol Brain Res. 1999 Oct 1;72(2):195-204.

PMID:
10529478
8.

The bovine mu-opioid receptor: cloning of cDNA and pharmacological characterization of the receptor expressed in mammalian cells.

Onoprishvili I, Andria ML, Vilim FS, Hiller JM, Simon EJ.

Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):129-37.

PMID:
10581406
9.

Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.

Divin MF, Bradbury FA, Carroll FI, Traynor JR.

Br J Pharmacol. 2009 Apr;156(7):1044-53. doi: 10.1111/j.1476-5381.2008.00035.x. Epub 2009 Feb 13.

10.

Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.

Zhang Y, Sham YY, Rajamani R, Gao J, Portoghese PS.

Chembiochem. 2005 May;6(5):853-9.

PMID:
15776407
11.

The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors.

Xu W, Chen C, Huang P, Li J, de Riel JK, Javitch JA, Liu-Chen LY.

Biochemistry. 2000 Nov 14;39(45):13904-15.

PMID:
11076532
12.

Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Li G, Aschenbach LC, Chen J, Cassidy MP, Stevens DL, Gabra BH, Selley DE, Dewey WL, Westkaemper RB, Zhang Y.

J Med Chem. 2009 Mar 12;52(5):1416-27. doi: 10.1021/jm801272c.

14.

Increased agonist affinity at the μ-opioid receptor induced by prolonged agonist exposure.

Birdsong WT, Arttamangkul S, Clark MJ, Cheng K, Rice KC, Traynor JR, Williams JT.

J Neurosci. 2013 Feb 27;33(9):4118-27. doi: 10.1523/JNEUROSCI.4187-12.2013.

15.

Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors.

Xu W, Li J, Chen C, Huang P, Weinstein H, Javitch JA, Shi L, de Riel JK, Liu-Chen LY.

Biochemistry. 2001 Jul 10;40(27):8018-29.

PMID:
11434771
17.
18.

Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.

Fowler CB, Pogozheva ID, Lomize AL, LeVine H 3rd, Mosberg HI.

Biochemistry. 2004 Dec 21;43(50):15796-810.

PMID:
15595835
19.

[Binding characteristics of new synthesized opioid receptor ligands to cloned mu opioid receptors stably expressed in CHO cell].

Hu P, Ye CY, Qiu ZB, Yang HF, Zhang DC.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Feb;25(1):79-82. Chinese.

PMID:
12905615
20.

A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling.

Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL.

J Biol Chem. 2001 Feb 2;276(5):3130-7. Epub 2000 Nov 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk